Fig. 1

Viability assessment for treatment with 5-FU and Olaparib. a, c MTT assay of HCT116 cells treated with 5-FU and/or Olaparib for 48 h and 72 h, respectively (n = 3). b, d MTT assay of HT29 cells treated with 5-FU and/or Olaparib for 48 h and 72 h, respectively (n = 3). Untreated cells were used as negative control (c). One-way ANOVA and Tukey’s post-hoc tests. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 above error bars vs. control; ^#p < 0.05 vs. 5-FU monotherapy in the same concentration